Oxaliplatin Modulates the Characteristics of Voltage-Gated Calcium Channels and Action Potentials in Small Dorsal Root Ganglion Neurons of Rats
- 325 Downloads
Oxaliplatin is important for treating colorectal cancer. Although oxaliplatin is highly effective, it has severe side effects, of which neurotoxicity in dorsal root ganglion (DRG) neurons is one of the most common. The key mechanisms of this neurotoxicity are still controversial. However, disturbances of calcium homeostasis in DRG neurons have been suggested to mediate oxaliplatin neurotoxicity. By using whole-cell patch-clamp and current-clamp techniques, as well as immunocytochemical staining, we examined the influence of short- and long-term exposure to oxaliplatin on voltage-gated calcium channels (VGCC) and different VGCC subtypes in small DRG neurons of rats in vitro. Exposure to oxaliplatin reduced VGCC currents (ICa(V)) in a concentration-dependent manner (1–500 μM; 13.8–63.3%). Subtype-specific measurements of VGCCs showed differential effects on ICa(V). While acute treatment with oxaliplatin led to a reduction in ICa(V) for P/Q-, T-, and L-type VGCCs, ICa(V) of N-type VGCCs was not affected. Exposure of DRG neurons to oxaliplatin (10 or 100 μM) for 24 h in vitro significantly increased the ICa(V) current density, with a significant influence on L- and T-type VGCCs. Immunostaining revealed an increase of L- and T-type VGCC protein levels in DRG neurons 24 h after oxaliplatin exposure. This effect was mediated by calcium-calmodulin-protein kinase II (CaMKII). Significant alterations in action potentials (AP) and their characteristics were also observed. While the amplitude increased after oxaliplatin treatment, the rise time and time-to-peak decreased, and these effects were reversed by treatment with pimozide and nimodipine, which suggests that VGCCs are critically involved in oxaliplatin-mediated neurotoxicity.
KeywordsNeuropathic pain Polyneuropathy Neurotoxicity Chemotherapy Ion channels Sensory neurons
This work was funded by Deutsche Forschungsgemeinschaft (DFG) (HA6202/4-1) and the Corona-Foundation (S199/10061/2016).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 4.Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, Limmroth V, Thomale J (2007) Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 27(35):9451–9457. https://doi.org/10.1523/JNEUROSCI.0523-07.2007 CrossRefPubMedGoogle Scholar
- 7.Xing C, Chen J, Xu H (1999) Changes in [Ca2+]i and IP3 levels in the process of cisplatin-induced apoptosis of gastric carcinoma. Zhonghua Zhong Liu Za Zhi [Chin J Oncol] 21(4):256–258Google Scholar
- 8.Splettstoesser F, Florea AM, Busselberg D (2007) IP(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br J Pharmacol 151(8):1176–1186. https://doi.org/10.1038/sj.bjp.0707335 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Leo M, Schmitt LI, Erkel M, Melnikova M, Thomale J, Hagenacker T (2017) Cisplatin-induced neuropathic pain is mediated by upregulation of N-type voltage-gated calcium channels in dorsal root ganglion neurons. Exp Neurol 288:62–74. https://doi.org/10.1016/j.expneurol.2016.11.003 CrossRefPubMedGoogle Scholar
- 17.Fuchs A, Rigaud M, Hogan QH (2007) Painful nerve injury shortens the intracellular Ca2+ signal in axotomized sensory neurons of rats. Anesthesiology 107(1):106–116. https://doi.org/10.1097/01.anes.0000267538.72900.68 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, Pages A, McRory J et al (2005) Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 24(2):315–324. https://doi.org/10.1038/sj.emboj.7600515 CrossRefPubMedGoogle Scholar
- 26.Deuis JR, Lim YL, de Sousa SR, Lewis RJ, Alewood PF, Cabot PJ, Vetter I (2014) Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin. Neuro-Oncology 16(10):1324–1332. https://doi.org/10.1093/neuonc/nou048 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Brown JV 3rd, Rettenmaier MA, Lopez KL, Graham C, Micha JP, Goldstein B (2008) A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 18(2):249–254. https://doi.org/10.1111/j.1525-1438.2007.01001.x CrossRefPubMedGoogle Scholar
- 32.Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, Orestes P, Latham JR et al (2009) In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain 145(1–2):184–195. https://doi.org/10.1016/j.pain.2009.06.012 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Zhang XF, Zhu CZ, Thimmapaya R, Choi WS, Honore P, Scott VE, Kroeger PE, Sullivan JP et al (2004) Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury. Brain Res 1009(1–2):147–158. https://doi.org/10.1016/j.brainres.2004.02.057 CrossRefPubMedGoogle Scholar
- 36.Li Y, Tatsui CE, Rhines LD, North RY, Harrison DS, Cassidy RM, Johansson CA, Kosturakis AK et al (2016) Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy. Pain. https://doi.org/10.1097/j.pain.0000000000000774 CrossRefGoogle Scholar